Uptake of radiolabelled herceptin by experimental mammary adenocarcinoma

Nuclear Medicine Review

Volumn 6, Issue 2, 2003, Pages 99-103

  Wiercioch, Rafal ^a   Balcerczak, Ewa ^a   Byszewska, Ewa ^b   Mirowski, Marek ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

Author keywords

Breast cancer; C erbB2; Herceptin; Receptor binding

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IODINE 131; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CANCER RADIOTHERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MODEL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC CODE; ISOTOPE LABELING; MOUSE; NONHUMAN; PROTEIN INTERACTION; RADIOACTIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; IODINE RADIOISOTOPES; ISOTOPE LABELING; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C3H; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0842301446     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Akiyma T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646.
2. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139.
3. Stern DF, Heffernan PA, Weinberg RA. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol 1986; 6: 1729-1740.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Levin WJ, Stuart SG, Udove J, Ulrich A. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
6. HER2 antibody for human cancer theraphy. Proc Natl Acad Sci USA 1992; 89: 4285-4289.
7. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu over expressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
8. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase II study of receptor - enhanced chemosensitivity using recombinant humanized anti-p185HER/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-2671.
9. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiotherapy and Oncol 1995; 43: 121-131.
10. Kalafonos HP, Pawlikowska TR, Hemingway A, Courtenay-Luck N, Dhokia B, Snook D, Sivolapenko GB, Hooker GR, McKenzie CG, Lavender PJ. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 1989; 30: 1636-1645.
11. 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer 1993; 67: 144-151.
12. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354.
13. Chomczyński P, Sacchi N. Single-step method of RNA isolation by acid guanidinum thiocynate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
14. Schwartz S, Caceres C, Morote J, De Tores I, Rodriguez-Vallejo J, Gonzalez J. Over-expression of epidermal growth factor receptor and c-erbB2/neu but not of int-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR. Int. J. Cancer 1998; 76: 464-467.
15. Tokunaga K, Taniguchi H, Yoda K, Shimizu M, Sakiyama S. Nucleotide sequence of a full-length cDNA for mouse cytoskeletal β-actine mRNA. Nucleic Acid Res 1986; 14: 2829-2836.
16. 131I-labeled human growth hormon of high specific radioactivity. Biochem J 1963; 89: 114-123.
17. Mirowski M, Świtalska J, Wiercioch R, Byszewska E, Niewiadomska H, Michalska M. Uptake of radiolabeled alpha-fetoprotein (AFP) by experimental mammary adenocarcinoma and adenoma: in vivo and in vitro studies. Nucl Med Commun 2003; 24: 297-303.
18. Ravdin PM, Chamness GC. The c-erbB2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromoleculear markers - a review. Gene 1995; 159: 19-27.
19. McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe KL, Carney WP. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product p185. Oncogene 1989; 4: 543-548.
20. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK. A monoclonal antibody against the c-erbB2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991; 51: 4575-4580.
21. Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Monoclonal antibodies directed to the erbB2 receptor inhibit in vivo tumour cell growth. Br J Cancer 1993; 68: 1140-1145.
22. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ulrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165-1172.
23. Payne RC, Allard JW, Anderson-Mauser L, Humphreys JD, Tenney DY, Moerris DL. Automated assay for HER-2/neu in serum. Clin Chem 2000; 46: 175-182.
24. Wu JT. C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment. Clin Chim Acta 2002; 322: 11-19.
25. Lee EJ, Oh EJ, Park YJ, Lee HK, Kim BK. Soluble transferring receptor (sTfR), ferritin, and sTfR/log ferritin index in anemic patients with non-hematologic malignancy and chronic inflammation. Clin Chem 2002; 48: 1118-1121.
26. Tesarova P, Kvasnicka J, Umlaufova A, Homokova H, Jirsa M, Tesar V. Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit 2000; 6: 661-667.
27. Kobayashi H, Sakahara H, Hosono M, Yao ZS, Toyama S, Endo K, Konishi J. Improved clearence of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a chase without decreased accumulation in the target tumor. J Nucl Med 1994; 35: 1677-1684.
28. Saga T, Neuman RD, Heya T, Sato J, Kinuya S, Le N., Paik CH, Weinstein JN. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA 1995; 92: 8999-9003.
29. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402-3408.
30. Behr TM, Behe M, Angerstein C, Griesinger F, Kaufmann CC, Wormann B, Emos G, Becker W. Does immunoscintigraphy allow for prognostic predictions with respect to the toxicity and therapeutic efficacy of herceptin immunotherapy of metastatic breast cancer. Eur J Nucl Med 2001: 976.
31. Kobayashi H, Shirakawa K, Kawamoto S, Saga T, Sato N, Hiraga A, Watanabe I, Heike Y, Togashi K, Konishi J, Brechbiel MW, Wakasugi H. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast agent G6-(1B4M-Gd)256. Cancer Res 2002; 62: 860-866.
32. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27: 536-544.
33. Slamon DJ, Leyland-Jones B, Shak S, Fuschs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001:344:783-792.